A Chinese clinical trial involved the use of autologous DC vaccines primed to induce LMP2-positive cell recognition [82]: 16 HLA-A2 patients with stage II-III NPC received vaccinations with autologous DCs pulsed with a HLA-A2-restricted LMP2A peptide. This evidence concerns the gene PSMB9 and nasopharyngeal carcinoma.